Relx (NYSE:RELX) Stock Rating Upgraded by StockNews.com

Relx (NYSE:RELX) was upgraded by investment analysts at StockNews.com from a “hold” rating to a “buy” rating in a research note issued to investors on Friday.

Separately, Redburn Atlantic began coverage on Relx in a research report on Wednesday, January 8th. They issued a “buy” rating for the company.

Relx Stock Down 1.5 %

Shares of RELX opened at $51.14 on Friday. The company has a current ratio of 0.48, a quick ratio of 0.42 and a debt-to-equity ratio of 1.63. Relx has a 52 week low of $40.25 and a 52 week high of $51.99. The stock has a fifty day moving average of $47.81 and a 200-day moving average of $47.15.

Hedge Funds Weigh In On Relx

A number of hedge funds have recently modified their holdings of RELX. JPMorgan Chase & Co. raised its position in Relx by 14.6% during the 3rd quarter. JPMorgan Chase & Co. now owns 826,481 shares of the technology company’s stock worth $39,225,000 after purchasing an additional 104,999 shares during the last quarter. CWA Asset Management Group LLC acquired a new stake in shares of Relx in the third quarter valued at about $548,000. Merit Financial Group LLC bought a new position in shares of Relx during the fourth quarter worth about $301,000. International Assets Investment Management LLC acquired a new position in shares of Relx in the third quarter worth approximately $1,268,000. Finally, Franklin Resources Inc. boosted its holdings in Relx by 3.3% in the third quarter. Franklin Resources Inc. now owns 18,429 shares of the technology company’s stock valued at $873,000 after acquiring an additional 588 shares during the last quarter. Institutional investors and hedge funds own 15.02% of the company’s stock.

About Relx

RELX Plc engages in provision of information and analytics solutions for professional and business customers across industries. It operates through the following business segments: Scientific, Technical & Medical; Risk & Business Analytics; Legal; and Exhibitions. The Scientific, Technical & Medical segment is a global information analytics business that helps institutions and professionals advance healthcare, open science, and improve performance for the benefit of humanity.